Recommendation Supports Use of KEYTRUDA for Certain Patients With Unresectable or Metastatic MSI-H/dMMR Colorectal, Gastric, Small Intestine or Biliary Cancer, as Well as Advanced or Recurrent MSI-H/dMMR Endometrial Carcinoma
https://finance.yahoo.com/news/merck-receives-positive-eu-chmp-130000423.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.